Bromide

Bromide

SCHEMBL2449969

[Br-].[Br-].c1ccc([P+](CCC[P+](c2ccccc2)(c2ccccc2)c2ccccc2)(c2ccccc2)c2ccccc2)cc1

nearest known ligand 0.74

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ACHECHKACHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGHRH2OPRM1

The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 9)

geneUniProtsupporting neighboursconfidence
HIF1A Q16665 1/20 0.74
ALDH1A1 P00352 1/20 0.54
CYP1A2 P05177 1/20 0.54
CYP2D6 P10635 1/20 0.54
TSHR P16473 1/20 0.54
CYP2C19 P33261 1/20 0.54
CHRNA7 P36544 9/20 0.47
TRAP1 Q12931 2/20 0.42
SNCA P37840 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL7970758 0.94 HIF1A (0.74) HIF1AALDH1A1CYP1A2CYP2D6TSHR
Bromide SCHEMBL2446042 0.94 HIF1A (0.74) HIF1AALDH1A1CYP1A2CYP2D6TSHR
Bromide SCHEMBL4184421 0.92 HIF1A (0.70) HIF1AALDH1A1CYP1A2CYP2D6TSHR
Bromide SCHEMBL8761335 0.92 HIF1A (0.70) HIF1AALDH1A1CYP1A2CYP2D6TSHR
Bromide SCHEMBL7634128 0.92 HIF1A (0.70) HIF1AALDH1A1CYP1A2CYP2D6TSHR
Bromide SCHEMBL3391859 0.92 HIF1A (0.70) HIF1AALDH1A1CYP1A2CYP2D6TSHR
Bromide SCHEMBL2450121 0.92 HIF1A (0.70) HIF1AALDH1A1CYP1A2CYP2D6TSHR
Bromide SCHEMBL52420 0.92 HIF1A (0.70) HIF1AALDH1A1CYP1A2CYP2D6TSHR
SCHEMBL31146915 0.92 HIF1A (0.78) HIF1AALDH1A1CYP1A2CYP2D6TSHR
Bromide SCHEMBL8999525 0.90 HIF1A (0.67) HIF1AALDH1A1CYP1A2CYP2D6TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030176740-A1 Solvent-free mechanochemical preparation of phosphonium salts, phosphorus ylides, and olefins IOWA STATE UNIVERSITY RESEARCH FOUNDATION, INC. 2003-09-18 US claimed
WO-2003066548-A2 SOLVENT-FREE MECHANOCHEMICAL PREPARATION OF PHOSPHONIUM SALTS, PHOSPHORUS YLIDES, AND OLEFINS IOWA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) 2003-08-14 WO claimed
US-10928728-B2 Photoactivable nitrogen bases BASF SE (DE) 2021-02-23 US disclosed
US-20210033972-A1 PHOTOACTIVABLE NITROGEN BASES BASF SE (DE) 2021-02-04 US disclosed
US-20180217498-A1 PHOTOACTIVABLE NITROGEN BASES BASF SE (DE) 2018-08-02 US disclosed
US-9921477-B2 Photoactivable nitrogen bases BASE SE (DE) 2018-03-20 US disclosed
EP-2145231-B1 PHOTOACTIVABLE NITROGEN BASES BASF SE (DE) 2011-09-14 EP disclosed
US-20100105794-A1 PHOTOACTIVABLE NITROGEN BASES CIBA CORPORATION (US) 2010-04-29 US disclosed
EP-2145231-A1 PHOTOACTIVABLE NITROGEN BASES BASF SE (DE) 2010-01-20 EP disclosed
WO-2008119688-A1 PHOTOACTIVABLE NITROGEN BASES BASF SE (CH) 2008-10-09 WO disclosed
US-7105714-B2 Phosphonium salt formation from a phosphine and a carbonium compound, ball milling to form the phosphorus ylide, phosphorylation of an aldehyde or ketone; one pot process; improved catalyst selectivity, efficiency; low temperature, industrial scale IOWA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) 2006-09-12 US disclosed
EP-1479687-A1 NOVEL 15-MEMBERED CYCLIC AZALIDE, NOVEL 16-MEMBERED CYCLIC DIAZALIDE DERIVATIVE, AND PROCESS FOR PRODUCING THESE MEIJI SEIKA KAISHA LTD. (JP) 2004-11-24 EP disclosed
US-6730812-B2 BALL-MILLING AND SALT FORMATION, CATALYTIC REACTION IN ONE POT; CATALYST SELECTIVITY, EFFICIENCY, LOW TEMPERATURE, SIMPLIFICATION; FORMING UNSATURATED COMPOUNDS, 4-BROMOSTYRENE, ISOPROPENYLNAPHTHALENE/1-/ IOWA STATE UNIVERSITY RESEARCH FOUNDATION, INC. 2004-05-04 US disclosed
US-20030176740-A1 Solvent-free mechanochemical preparation of phosphonium salts, phosphorus ylides, and olefins IOWA STATE UNIVERSITY RESEARCH FOUNDATION, INC. 2003-09-18 US disclosed
WO-2003066548-A2 SOLVENT-FREE MECHANOCHEMICAL PREPARATION OF PHOSPHONIUM SALTS, PHOSPHORUS YLIDES, AND OLEFINS IOWA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) 2003-08-14 WO disclosed
EP-0970085-B1 PHOTOACTIVATABLE NITROGEN-CONTAINING BASES BASED ON ALPHA-AMINO ALKENES CIBA SC HOLDING AG (CH) 2002-07-24 EP disclosed
WO-2002044128-A2 SALICYLATE ANALOGS AS INTERLEUKIN-4 ANTAGONISTS SUNESIS PHARMACEUTICALS, INC. (US) 2002-06-06 WO disclosed
US-6087070-A AS PHOTOINITIATORS FOR BASE-CATALYZABLE REACTIONS CIBA SPECIALTY CHEMICALS CORPORATION (US) 2000-07-11 US disclosed
EP-0970085-A1 PHOTOACTIVATABLE NITROGEN-CONTAINING BASES BASED ON $g(a)-AMINO ALKENES Ciba SC Holding AG (CH) 2000-01-12 EP disclosed
WO-1998041524-A1 PHOTOACTIVATABLE NITROGEN-CONTAINING BASES BASED ON α-AMINO ALKENES CIBA SPECIALTY CHEMICALS HOLDING INC. (CH) 1998-09-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210033972-A1 PHOTOACTIVABLE NITROGEN BASES CBR1, ARNT, NR0B1 HIF1A 1258/4885ALDH1A1 1659/4885CYP1A2 73/4885
US-10928728-B2 Photoactivable nitrogen bases CBR1, NR0B1, NR0B2 HIF1A 1136/4885ALDH1A1 1733/4885CYP1A2 81/4885
US-20030176740-A1 Solvent-free mechanochemical preparation of phosphonium salts, phosphorus ylides, and olefins CCR4, CCR1, CCR6 HIF1A 4606/4885ALDH1A1 4791/4885CYP1A2 4750/4885
US-20180217498-A1 PHOTOACTIVABLE NITROGEN BASES CBR1, NR0B1, NR0B2 HIF1A 1136/4885ALDH1A1 1733/4885CYP1A2 81/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.